PNC Financial Services Group
CRDL

PNC Financial Services Group’s Cardiol Therapeutics CRDL Stock Holding History

PNC Financial Services Group’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$49 – 4753
2023
Q1 		$49 Buy
+100
New +$59 ﹤0.01% 4643

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AI
AXS Investments Port Chester, New York $248M AUM 15.95% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PNC Financial Services Group's CRDL Position: Q2 2023 in Review

PNC Financial Services Group sold out of Cardiol Therapeutics (CRDL) in Q2 2023, closing a stake of 100 shares — an estimated $49 sold.

PNC Financial Services Group first reported a position in CRDL in Q1 2023 and held it in 1 quarter. The position peaked at $49 in Q1 2023. 33 funds tracked by Wall St. Rank hold CRDL as of Q2 2023.

  • PNC Financial Services Group reported no remaining Cardiol Therapeutics position as of Q2 2023 after selling out during the quarter.
  • PNC Financial Services Group sold 100 Cardiol Therapeutics shares in Q2 2023, an estimated $49.
  • PNC Financial Services Group first reported a position in Cardiol Therapeutics in Q1 2023 and held it in 1 quarter.
  • PNC Financial Services Group's Cardiol Therapeutics position peaked at $49 in Q1 2023.
  • 33 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2023.

Based on PNC Financial Services Group's 13F filing for Q2 2023, filed 11 Aug 2023.